Cargando…
Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis
BACKGROUND: In patients with end stage renal disease and atrial fibrillation (AF), undergoing chronic dialysis, direct oral agents are contraindicated and warfarin does not fully prevent embolic events while increasing the bleeding risk. The high hemorrhagic risk represents the main problem in this...
Autores principales: | Genovesi, Simonetta, Porcu, Luca, Slaviero, Giorgio, Casu, Gavino, Bertoli, Silvio, Sagone, Antonio, Buskermolen, Monique, Pieruzzi, Federico, Rovaris, Giovanni, Montoli, Alberto, Oreglia, Jacopo, Piccaluga, Emanuela, Molon, Giulio, Gaggiotti, Mario, Ettori, Federica, Gaspardone, Achille, Palumbo, Roberto, Viazzi, Francesca, Breschi, Marco, Gallieni, Maurizio, Contaldo, Gina, D’Angelo, Giuseppe, Merella, Pierluigi, Galli, Fabio, Rebora, Paola, Valsecchi, Mariagrazia, Mazzone, Patrizio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881969/ https://www.ncbi.nlm.nih.gov/pubmed/32535831 http://dx.doi.org/10.1007/s40620-020-00774-5 |
Ejemplares similares
-
Correction to: Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis
por: Genovesi, Simonetta, et al.
Publicado: (2020) -
Long-term safety and efficacy of left atrial appendage occlusion in dialysis patients with atrial fibrillation: a multi-center, prospective, open label, observational study
por: Genovesi, Simonetta, et al.
Publicado: (2023) -
Left Atrial Appendage Occlusion in High Bleeding Risk Patients
por: Merella, Pierluigi, et al.
Publicado: (2019) -
Some good reasons to proceed with the occlusion of the auricle
por: Casu, Gavino, et al.
Publicado: (2022) -
Percutaneous Left Atrial Appendage Occlusion: What the Practising Physician Should Know
por: Merella, Pierluigi, et al.
Publicado: (2023)